Posted by Michael Wonder on 16 Dec 2021
ICER publishes final evidence report and policy recommendations on tezepelumab for severe asthma
16 December 2021 - Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tezepelumab added to standard of care in individuals with severe asthma.
The ICER today released a Final Evidence Report assessing the comparative clinical effectiveness and value of tezepelumab (Amgen, AstraZeneca) for the treatment of severe asthma.
